ACTEMRA is not FDA-approved for use in severe COVID-19 pneumonia.

ACTEMRA is a monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin-6 (IL-6) is a cytokine that plays an important role in immune responses.

Genentech, a member of the Roche group, initiated three Phase 3 and one Phase 2 clinical trials to evaluate ACTEMRA in COVID-19 associated pneumonia. Information on these trials may be found in the “COVID-19 Clinical Trials” section of this website or by accessing www.clinicaltrials.gov.

UPDATE: On July 28, Genentech announced that the Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter COVACTA study did not meet its primary endpoint of showing improved clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia. The study also failed to meet key secondary endpoints, including reduced patient mortality.

This website is intended to make available, in a transparent manner, the information we have on the use of ACTEMRA for COVID-19 pneumonia to enable physicians to make informed individual patient treatment decisions. The ultimate decision to use ACTEMRA for COVID-19 pneumonia patients remains with the treating physician.

Genentech Medical Resources

Up-to-date information on ACTEMRA

COVID-19 Clinical Trials

Roche-Sponsored Clinical Trials in COVID-19 

Health Authority Information

Select Links to External Health Authority Resources

Contact Information

Report Adverse Events (AEs) 

(888) 835-2555

Submit a Form

24 hrs/day, 7 days/week

Medical Questions about Genentech Medicine

(800) 821-8590

24 hrs/day, 7 days/week

Report Product Complaint

(800) 334-0290

Monday - Friday, 5am - 5pm PT

Clinical Trial Information

(888) 662-6728

Monday - Friday, 5am - 5pm PT

Providers, Wholesalers & Distributors Product Supply Questions Genentech Customer Service

(800) 551-2231

Additional Information here

Monday - Friday, 6am - 5pm PT

Connect Virtually with a Medical Science Liaison

Submit a Form

Indication

ACTEMRA is indicated for the treatment of:

  • Adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  • Adult patients with giant cell arteritis (GCA)
  • Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (PJIA) in patients
  • Patients 2 years of age and older with active systemic juvenile idiopathic arthritis (SJIA)
  • Adults and pediatric patients 2 years of age and older with chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome.

Important Safety Information

Boxed Warning: Risk of Serious Infections

Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic infections have occurred in patients receiving ACTEMRA. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. Perform test for latent TB; if positive, start treatment for TB prior to starting ACTEMRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative.

Apr 2020 - Shipping short-dated ACTEMRA (tocilizumab) 400 mg/20 mL vial for IV with dark blue cap